Malta’s 40,000 arthritis sufferers can benefit from this treatment.

After its success around the world, a revolutionary new arthritis product, Flexiseq, is being launched in Malta by Pro Bono Bio International Trading Ltd, a Maltese medical device specialist and leader in nano-physical healthcare products.

Nick Baverstock, Pro Bono Bio’s country manager in Malta said: “We are very pleased that Malta’s 40,000 arthritis sufferers can now benefit from such a ground-breaking treatment and we look forward to hearing feedback from patients and doctors soon.”

Flexiseq does not contain an active pharmaceutical ingredient and therefore does not require a prescription. It works through a patented physical mode of action that increases the level of bio-lubrication in the affected joint.

The product offers a treatment option that is safe for everyone to use. Its proven effectiveness comes with significant advantages as the product has no contra-indications, contains no drugs (and so cannot cause drug-to-drug interactions) and, with over six million doses administered since it was first launched, there have been no reported systemic side effects.

Michael Earl, Pro Bono Bio chief operating officer, said: “The proven physical mode of action and the lack of an active pharmaceutical ingredient give Flexiseq the best of both worlds: it works and it’s safe.”

The unique product has been very well received by each of its launch markets, generating approval from key opinion leaders, pharmacists and arthritis charities who are fully aware of the limitations of conventional pain medications and the solution that Flexiseq provides.

The award-winning product is already on sale in various European markets as well as in countries such as Malaysia and Singapore. In Germany, it won the Innovation Award 2013 from the Federal Association of German Pharmacists, and when it was launched in Ireland in June, Flexiseq became the fastest growing over-the-counter product that pharmacies there had seen in recent times.

In the UK, the product is supported by one of Europe’s largest arthritis charities, Arthritis Research UK.

Pro Bono Bio is an innovative healthcare and nano medical device company launched in 2011. It launched Flexiseq in Europe in 2012 and plans to launch two further new products for the treatment of inflammatory skin disorders this year.

For more information, call 2144 6205.

www.flexiseq.com
www.probonobio.com